Thymic Neuroendocrine Tumors: Evolving Insights and Innovative Approaches

Area of Science:

• Oncology
• Endocrinology
• Rare Cancers

Background:

• Thymic neuroendocrine tumors (TNENs) are exceptionally rare and heterogeneous malignancies.
• Diagnosis often occurs at advanced stages, with limited standardized treatment protocols.
• Current therapeutic strategies are largely extrapolated from other neuroendocrine neoplasms.

Purpose of the Study:

• To provide an updated overview of current and emerging treatment approaches for TNENs.
• To focus on histology-driven strategies and the evolving roles of targeted and radionuclide therapies.
• To integrate findings from retrospective series, real-world data, and ongoing clinical trials.

Main Methods:

• Conducted a comprehensive literature search of PubMed/MEDLINE and Embase (January 2000 - May 2025).
• Included retrospective series, real-world data, and ongoing clinical trials.
• Focused on histology-driven strategies and novel therapeutic modalities.

Main Results:

• Surgical resection is the primary treatment for resectable TNENs.
• Multimodal approaches (chemotherapy, radiotherapy) are crucial for thymic neuroendocrine carcinomas.
• Somatostatin analogues, everolimus, cabozantinib, and peptide receptor radionuclide therapy show promise for specific TNEN subtypes.

Conclusions:

• TNEN management requires a multidisciplinary, individualized approach based on subtype and aggressiveness.
• Limited robust prospective data necessitate further research.
• Integration into basket trials and dedicated multicenter studies are crucial for optimal treatment algorithms.